Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice

Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental dermatology 2024-08, Vol.33 (8), p.e15152-n/a
Hauptverfasser: Butrón‐Bris, B., Llamas‐Velasco, M., Ovejero‐Benito, M. C., Santos‐Juanes, J., Martínez‐López, A., Ruiz‐Villaverde, R., Roustan, G., Baniandrés, O., Izu‐Belloso, R., Cueva, P., Sahuquillo‐Torralba, A., Gónzalez‐Quesada, A., Vilarrasa‐Rull, E., Pujol‐Montcusí, J., García‐Martínez, J., Navares, M., Palomar‐Moreno, I., Novalbos, J., Abad‐Santos, F., Daudén, E., Fuente, H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real‐life clinical practice. Ninety patients with plaque psoriasis recruited from—Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR 27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 (TNFAIP3), CT for rs9373839 (ATG5), and delCTGT/delCTGT for rs72167053 (PDE4D) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 (IL17RC) was protective, independently of weight and disease duration (FDR 76 kg) and disease duration (>27 years), showed a sensitivity of 88.5% and specificity of 83.3% to discriminate responders (PASI ≤1) and non‐responders (PASI >1) at 12 months.
ISSN:0906-6705
1600-0625
1600-0625
DOI:10.1111/exd.15152